Table 1.

In vitro potency of free drugs and CD22-ADCs

IC50 (95% CI)BJAB.LucGranta-519SuDHL4.LucWSU-DLCL2
MMAE (nmol/L)0.54 (0.49–0.60)0.25 (0.23–0.27)1.19 (1.15–1.22)0.25 (0.24–0.27)
PNU-159682 (nmol/L)0.10 (0.09–0.11)0.020 (0.018–0.023)0.055 (0.050–0.060)0.1a
control-vc-MMAE (μg/mL)>10>10>10>10
anti-CD22-vc-MMAE (μg/mL)1.1 (1.0–1.3)0.55 (0.45–0.68)0.95 (0.85–1.06)0.014 (0.013–0.015)
control-NMS249 (μg/mL)2.4 (1.4–4.0)1.96 (1.88–2.04)2.88 (2.84–2.92)1.9 (1.7–2.3)
anti-CD22-NMS249 (μg/mL)0.058 (0.056–0.059)0.030 (0.027–0.032)0.0221 (0.0217–0.0225)0.010 (0.095–0.012)
  • aCurve fit was ambiguous, CI value was too wide to report.